1. Up-regulation of acyl-coenzyme A:cholesterol acyltransferase (ACAT) in nephrotic syndrome 
Nosratola D. Vaziri, M.D., Kaihui Liang 
Kidney International 
Volume 61, Issue 5, Pages (May 2002)
DOI: /j x
Copyright © 2002 International Society of Nephrology Terms and Conditions

2. Figure 1
Representative Western blots (upper panel) and group data illustrating hepatic tissue acyl-CoA:cholesterol acyltransferase (ACAT) protein abundance in the nephrotic (NS), Nagase hypoanalbuminemic (NAG) and normal control (NL) groups. N = 6 in each group. P <
Kidney International  , DOI: ( /j x)
Copyright © 2002 International Society of Nephrology Terms and Conditions

3. Figure 2
Representative Northern blots (upper panel) and group data (lower panel) depicting hepatic tissue ACAT and GAPDH mRNA abundance in the nephrotic (NS), Nagase hypoanalbuminemic (NAG) and normal control (NL) groups. N = 6 in each group. P < 0.01.
Kidney International  , DOI: ( /j x)
Copyright © 2002 International Society of Nephrology Terms and Conditions

4. Figure 3
Hepatic microsomal ACAT enzymatic activity in nephrotic (NS), Nagase hypoanalbuminemic (NAG) and normal control (NL) groups. N = 6 in each group. P < 0.01.
Kidney International  , DOI: ( /j x)
Copyright © 2002 International Society of Nephrology Terms and Conditions

5. Figure 4
Correlations between hepatic tissue ACAT protein abundance and serum cholesterol concentration (A), urinary protein excretion (B) and plasma albumin (C) in the normal control (NL; •), nephrotic syndrome (NS; ○) and Nagase hypoalbuminemic (NG; ▾) groups. In A, r = 0.95, P < 0.01; in B, r = 0.93, P < 0.01; in C, r = 0.06, P = NS.
Kidney International  , DOI: ( /j x)
Copyright © 2002 International Society of Nephrology Terms and Conditions